Carbamazepine intravenous - Lundbeck

Drug Profile

Carbamazepine intravenous - Lundbeck

Alternative Names: Carbamazepine IV; Carbella™; Carnexiv

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OVATION Pharmaceuticals
  • Developer Ligand Pharmaceuticals; Lundbeck Inc
  • Class Antidepressants; Antiepileptic drugs; Antimanics; Dibenzazepines; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epilepsy
  • New Molecular Entity No

Highest Development Phases

  • Marketed Epilepsy

Most Recent Events

  • 22 Apr 2017 Pharmacodynamics and pharmacokinetics data from a phase I safety trial in Epilepsy presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 07 Oct 2016 Registered for Epilepsy in USA (IV)
  • 22 Apr 2016 US FDA accepts resubmission of NDA for carbamazepine intravenous for Epilepsy for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top